Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Study P1093
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors ViiV Healthcare
- 08 Aug 2017 Planned number of patients changed from 40 to 80.
- 08 Aug 2017 Planned primary completion date changed from 12 Apr 2019 to 29 Dec 2023.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.